miR-16 在 T 淋巴母细胞淋巴瘤 / 急性淋巴母细胞白血病中表达简 |
| |
引用本文: | 童来根,吴文忠,张云平,周志刚,陈亚峰,黄文娟,许欢,苏倩倩. miR-16 在 T 淋巴母细胞淋巴瘤 / 急性淋巴母细胞白血病中表达简[J]. 中国实验血液学杂志, 2014, 0(1): 99-103 |
| |
作者姓名: | 童来根 吴文忠 张云平 周志刚 陈亚峰 黄文娟 许欢 苏倩倩 |
| |
作者单位: | 宜兴市人民医院血液内科,江苏宜兴214200 |
| |
摘 要: | 本研究探讨miR-16在T淋巴母细胞淋巴瘤/急性淋巴母细胞白血病(T-LBL/ALL)中的表达及其与预后的关系.应用免疫组织化学法对宜共市人民医院血液科有详细随访资料的38例T-LBL/ALL石蜡标本进行CD3、cCD3、CD10、CD20、CD34、CD43、CD99、TdT、PAX-5、BCL-2和Ki67免疫组织化学标记检测,采用real-time RT-PCR方法检测miR-16的表达水平,以15例淋巴结反应性增生作为对照.结果表明:38例T-LBL/ALL中TdT阳性率最高(94.7%),CD34阳性最低(22.1%),PAX-5及CD20为阴性.在39.5%病例中Ki67大于80%.与淋巴结反应性增生相比较,miR-16在T-LBL/ALL中表达上调,其表达量是淋巴结反性增生的4.87倍(P<0.05).T-LBL中miR-16高表达组总体生存率下降(P<0.05).BCL-2蛋白表达阳性组预后优于阴性组预后(P<0.05).miR-16表达与BCL-2蛋白存在相关性(r=0.51,P<0.05).结论:在T-LBL/ALL中miR-16的高表达组总体生存率明显高于低表达组,提示miR-16可能与预后有相关性,而BCL-2蛋白表达阳性组预后好于阴性组,可能也是一种影响预后的因素.
|
关 键 词: | miR-16 淋巴瘤 T淋巴母细胞淋巴瘤 急性淋巴母细胞白血病 |
Expression of miR-16 in Patients with T Lymphoblastic lymphoma/Acute Lymphoblastic Leukemia |
| |
Affiliation: | TONG Lai-Gen;WU Wen-Zhong;ZHANG Yun-Ping;ZHOU Zhi-Gang;CHEN Ya-Feng;HUANG Wen-Juan;XU Huan(Department of Hematology, Yixing Municipal People's Hospital, Yixing, 2t4200, Jiangsu Province ,China) |
| |
Abstract: | This study was purposed to investigate the expression of miR-16 in T lymphoblastic lymphoma/acute lymphoblastic leukemia (T-LBL/ALL) and its relation with target therapy and prognosis.The CD3、cCD3 、CD10、CD20 、CD34、CD43、CD99、TdT、PAX-5、BCL-2 and Ki67 in paraffin samplcs from 38 cases of T-LBL/ALL were detected by immunohistochemical labeling; the miR-16 expression level was detected by real-time RT-PCR.Fifteen cases of reactive hyperplasia of lymphonodes were selected as control.The results indicated that among 38 cases of T-LBL/ALL the positive rate of TdT was highest (94.7%),the positive rate of CD34 was lowest (22.1%),the PAX-5 and CD20 were found to be negative.The Ki67 expression level in 39.5% cases exceeded 80%.As compared with reactive hyperplasia of lymphonode,the miR-16 expression in T-LBL/ALL was up-regulated,ant its expression level was 4.87-fold of reactive hyperplasia of lymphonode (P < 0.05).The overall survival rate in group of miR-16 high expression decreased (P < 0.05).The prognosis of T-LBL/ALL patients with BCL-2 positive expression was better than that of patients with BCL-2 negative expression (P < 0.05).The miR-1 6 expression correlated with BCL-2 protein (r =0.51,P <0.05).It is concluded that the overall survival rate in miR-16 high expression group is higher than that in miR-16 low expression group,suggesting possible relation of miR-16 with prognosis.Moreover,the prognosis in BCL-2 positive expression group is better than that in negative expression group,which may be a factor influencing prognosis. |
| |
Keywords: | miR-16 lymphoma T lymphoblastic lymphome acute lymphoblastic leukemia |
本文献已被 CNKI 维普 等数据库收录! |
|